drugset
drugset / Trial / NCT01332227

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227 ↗

Phase 4 Completed 132 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether HIV-1-infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or tolerability issues, will maintain virologic suppression after switching to a regimen of heat-stable ritonavir boosted atazanavir, 300/100 mg, once daily plus raltegravir, 400 mg, twice daily.

Timeline

Start
2011-10
Primary completion
2013-09
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified 400 mg Oral
Subject Tenofovir/Emtricitabine Unknown 200 mg Oral
Subject Tenofovir/Emtricitabine Unknown 300 mg Oral
Background Atazanavir Other / unclassified 300 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral

Indications

No indication recorded.